Latest Deals

The move follows Musk stepping down as an adviser to Trump. Credit: kovop/Shutterstock

Neuralink has secured $650m in a Series E financing round. This latest financial boost is aimed at expanding the reach of the company’s devices, which are said to restore independence for individuals with severe medical conditions. The round saw contributions from a host of investors, including DFJ Growth, ARK Invest, Founders Fund, and Human Capital.

Merit Medical Systems has acquired US-based Biolife Delaware, a manufacturer of haemostatic devices, in a $120m deal. The transaction value was paid in cash alongside the assumption of Biolife’s liabilities. The acquisition enhances Merit’s offerings, providing clinicians with products aimed at streamlining post-procedure care. 

Salvia BioElectronics has raised €53m ($60m) in a Series B funding round towards advancing its non-invasive approach to treating chronic migraine. The Dutch startup’s MySalvia therapy for individuals with chronic migraine uses implants that target key nerves involved in migraine, aiming to reduce the frequency and intensity of migraine attacks. 

23andMe has found itself a buyer after biotech Regeneron won an auction to buy the bankrupt genetics company for $256m. As part of a court-supervised sale, the auction will see Regeneron acquire the majority of 23andMe’s assets. This includes the company’s Personal Genome Service (PGS) and Total Health and Research Services business lines, but not the Lemonaid Health subsidiary. Lemonaid Health, a telehealth company, will be wound down by 23andMe separately.